Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Increasing monoclonal antibody capacity for process development and GMP production at U.S. and U.K. Sites
November 10, 2017
By: Tim Wright
Editor-in-Chief, Contract Pharma
Fujifilm Corporation has unveiled plans to invest roughly $30 million in its CDMO sites in the U.S. and the UK. In addition to investing approximately $20 million in a GMP facility dedicated to the production of monoclonal antibodies at the Fujifilm Diosynth Biotechnologies (FDB) site in College Station, TX, the company is also investing approximately $10 million at its Wilton Centre site in Redcar, UK, to expand the floor area of the development site of production processes for antibodies and install an additional facility. The new investment will expand the existing Saturn mAb3 Process Development Laboratories dedicated to the development of monoclonal antibodies under FDB’s Platform. From Fall 2018 onwards, the new facilities will ramp up operation, bolstering the company’s ability to accept orders from its customers for process development and manufacturing in the field of antibodies. In March 2017, Fujifilm established the company’s Bio CDMO Division which oversees the expansion of its contract development and manufacturing business focused on FDB. The company is working to strengthen its business capacity through measures including the installation of three single-use 4 2,000-liter mammalian cell culture tanks, scheduled to begin operation early 2018 in the cGMP-compliant production facility that has recently been completed at Texas site as well as the company’s new UK facility that opened in September. In order to respond to growing customer needs in this field, Fujifilm has decided to make additional investments earlier than scheduled. Three new single-use 2,000-liter mammalian cell culture tanks are to be installed at the Texas facility for a total of six tanks. In addition, the company will be expanding the floor area of process development site in the U.K. to nearly double the existing space of approximately 930 square meters while also expanding the range of state-of-the-art equipment with the latest high-throughput technologies, including fully automated bioreactors and chromatography systems, to enable for rapid and efficient monoclonal antibody manufacturing process readiness. These measures will bolster the company’s contract development and manufacturing business by using the Saturn mAb platform for the process development and manufacturing of antibodies. At the Texas site, the new production block has sufficient space for expansion up to a maximum of 12 cell culture tanks, which will allow the company to respond promptly to customer demands for increased production and future demand growth.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !